This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Vera Therapeutics (VERA) and Resmed (RMD)

Tipranks - Tipranks - Thu Jun 4, 6:36AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on PROCEPT BioRobotics (PRCT), Vera Therapeutics (VERA) and Resmed (RMD).

Claim 55% Off TipRanks

PROCEPT BioRobotics (PRCT)

BTIG analyst Ryan Zimmerman maintained a Hold rating on PROCEPT BioRobotics yesterday. The company’s shares closed last Tuesday at $26.76.

According to TipRanks.com, Zimmerman is a 2-star analyst with an average return of 0.6% and a 40.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Shoulder Innovations, Inc., and Tactile Systems Technology. ;'>

Currently, the analyst consensus on PROCEPT BioRobotics is a Moderate Buy with an average price target of $33.67, which is a 21.2% upside from current levels. In a report issued on May 21, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $29.00 price target.

See today’s best-performing stocks on TipRanks >>

Vera Therapeutics (VERA)

In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics, with a price target of $56.00. The company’s shares closed last Tuesday at $31.26.

According to TipRanks.com, Divan is a 5-star analyst with an average return of 10.2% and a 55.2% success rate. Divan covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Unicycive Therapeutics, and Assembly Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $77.63 average price target, a 125.4% upside from current levels. In a report issued on May 22, J.P. Morgan also maintained a Buy rating on the stock with a $86.00 price target.

Resmed (RMD)

William Blair analyst Brandon Vazquez maintained a Buy rating on Resmed today. The company’s shares closed last Tuesday at $182.82, close to its 52-week low of $172.19.

According to TipRanks.com, Vazquez ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -9.4% and a 34.0% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Edwards Lifesciences, and Irhythm Technologies. ;'>

Currently, the analyst consensus on Resmed is a Moderate Buy with an average price target of $264.56, representing a 44.7% upside. In a report released today, TipRanks – xAI also upgraded the stock to Buy with a $213.00 price target.

Read More on PRCT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).